Paul Newhouse, M.D.
Jim Turner Professor of Cognitive Disorders;
Professor of Psychiatry & Behavioral Sciences, Pharmacology, and Medicine; Director, Vanderbilt Center for Cognitive Medicine; Physician-Scientist, VA-TVHS GRECC
Overview of Interests
Paul Newhouse directs the Vanderbilt Center for Cognitive Medicine. This multidisciplinary laboratory is focused on human research studies that investigate the biological, neurochemical, and brain circuitry mechanisms that underlie changes that occur in cognitive functioning associated with pathological development, normal aging, and gender-related differences using cognitive psychology, neuropharmacology, and functional magnetic resonance imaging (fMRI). Dr. Newhouse's research has focused on central nicotinic mechanisms in degenerative brain disorders and the role of nicotinic receptor systems in normal and disordered cognitive functioning in humans. He has also focused attention on the development of novel nicotinic agents for clinical use. Another major focus includes studying the interaction of estrogen and central cholinergic, catecholaminergic, and serotonergic systems in relation to cognitive and emotional aging in the elderly and novel pharmacologic-imaging methodologies. Other interests include treatment of depression and behavioral disturbances, and development of effective novel agents for the treatment of neuropsychiatric disorders. Of particular interest is cognitive impairment that is secondary to the development of complex neuropsychiatric disorders, including Alzheimer's disease, as well as neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) and Down syndrome (DS).